The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.
Most HIV prevention drugs are daily pills (known as PrEP), which many people struggle to take regularly for various reasons, including inconvenience, price, stigma and side-effects. Lenacapavir works differently. It’s a new type of drug that attacks HIV’s protective shell, stopping the virus from copying itself at multiple stages.
In recent years, two other long-acting medicines have been developed for HIV, but neither of them offers protection for a full six months like lenacapavir.
